Latest News - Verbund AG
Top Corporates Hub
Verbund AG
Edwards boosts FY25 outlook after Q3 surpasses expectations
31.10.2025 11:56
Edwards Q3 2025 revenues grew to $1.55bn, reflecting an uplift of 14.7% from around $1.35bn in Q3 2024.
Edwards Lifesciences Corp (EW) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
31.10.2025 03:05
Edwards Lifesciences Corp (EW) reports a 12.6% revenue increase and raises full-year sales and EPS guidance, showcasing robust performance across therapeutic areas.
Why Edwards Lifesciences (EW) Is Up 7.6% After Positive Long-Term Data for SAPIEN Valve Platform
30.10.2025 03:14
In recent days, Edwards Lifesciences announced positive long-term clinical trial results for its SAPIEN TAVR technology and successful patient outcomes from real-world data on the SAPIEN M3 and EVOQUE valve systems at the annual TCT symposium. These data highlighted superior valve performance, durability, and quality-of-life improvements for patients with mitral and tricuspid valve disease, supporting Edwards’ leadership in structural heart therapies. The simultaneous presentation of...
Why Analysts Say Edwards Lifesciences Story Is Evolving With New Data and Market Shifts
30.10.2025 00:14
Edwards Lifesciences has seen its consensus analyst price target inch higher, rising from $87.73 to $88.83 as market sentiment improves. This slight increase is supported by a mix of optimism and caution in recent analyst commentaries, driven by promising clinical data and evolving market expectations. Stay tuned to learn how you can stay ahead of shifts in the Edwards Lifesciences narrative as new information becomes available. What Wall Street Has Been Saying ? Bullish Takeaways Jefferies...
Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls
29.10.2025 13:35
Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls
Osterweis Opportunity Fund Q3 2025 Picks: AI Foundational Infrastructure Companies
29.10.2025 04:30
Osterweis Capital Management reviews Q3 2025 small cap growth trends, highlighting AI tailwinds, key exits, and standout performers. Read the full investor update.
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
13.10.2025 12:14
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus
10.10.2025 12:44
ABT's Q3 results may show strength in Medical Devices and Nutrition, offsetting softness in Diagnostics.
Edwards Lifesciences (EW): Assessing Valuation Following Recent Share Price Decline
10.10.2025 05:08
Edwards Lifesciences (EW) has seen its stock trend lower over the past month, down about 6%. Investors are keeping an eye on recent performance and fundamentals as they review the company’s latest results and outlook. See our latest analysis for Edwards Lifesciences. Despite some recent weakness in the share price, with a 1-month share price return of -5.8%, Edwards Lifesciences still boasts a 1-year total shareholder return of 10.2%. While momentum has faded since the start of the year, its...
TLRY Gears Up to Report Q1 Earnings: Cannabis Recovery in Focus
08.10.2025 15:16
Tilray Brands' fiscal first-quarter report is likely to highlight international cannabis gains, European expansion and wellness growth.
Netflix upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
07.10.2025 13:50
Netflix upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
The Returns On Capital At Edwards Lifesciences (NYSE:EW) Don't Inspire Confidence
23.09.2025 14:00
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
A Look At The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
01.09.2025 12:00
Key Insights Using the 2 Stage Free Cash Flow to Equity, Edwards Lifesciences fair value estimate is US$81.42 Current...
Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer
25.08.2025 08:42
Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer.
Global Non-invasive Brain Trauma Monitoring Device Market Size/Share Worth USD 32.19 Billion by 2034 at a 8.13% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
21.08.2025 11:30
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Non-invasive Brain Trauma Monitoring Device Market size & share revenue was valued at approximately USD 14.7 Billion in 2024 and is expected to reach USD 14.98 Billion in 2025 and is expected to reach around USD 32.19 Billion by 2034, at a CAGR of 8.13% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Na
Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase
19.08.2025 20:15
IRVINE, Calif., August 19, 2025--Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $500 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025.
FTC to block Edwards Lifesciences’ acquisition of JenaValve due to competitive concerns
15.08.2025 09:57
JenaValve is in the process of obtaining FDA approval for the first transcatheter aortic valve to address aortic regurgitation.
FTC files lawsuit to halt Edwards acquisition of JenaValve
07.08.2025 11:26
The FTC asserts that Edwards acquisition of JenaValve, given it now owns rival TAVR-AR firm JC Medical, will eliminate competition in the US artificial heart valve market.